Skip to main content

Edward M. Messing, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2838

Administrative: (585) 275-5120

Fax: (585) 273-1068

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Surgery, Urology


I chose this field because half of all cancers in men – and almost 20% in women – arise in urologic organs and are treated by urologists. Specializing in urologic oncology is a way of helping many people.

Since I believe that an informed patient makes the wisest decisions regarding treatment, I spend much time educating my patients about their disease and options for treatment. My approach to patient care is individualized, both in terms of treatments offered and recommended, and in terms of the patient's and his or her family's goals. Treating bladder, kidney, prostate and testicular cancer are among my areas of expertise. I also hold several research grants and patents related to the field of urologic cancer.

Conditions I Treat:

- Bladder cancer
- Kidney cancer
- Prostate cancer
- Testicular cancer
- Adrenal cancer
- Penile cancer
- Scrotal cancer
- Ureteral cancer
- Urethral cancer

Professional Background

Dr. Messing received his MD degree from New York University in 1972, had his surgery training at NYU-Bellevue Hospital in New York 1972-1974, and his Urology Residency at Stanford University 1974-1978. After 2 years on the faculty at Tulane University, he completed a fellowship in Urologic Oncology at UCLA in 1982. He was on the faculty of the Division of Urology at the University of Wisconsin from 1982-1995, being Director of their Urologic Oncology Program for the last 10 years. He became The W.W. Scott Professor and Chairman of the Department of Urology and maintained that position until he stepped down as Chairman in January, 2018. He remains an active clinician and surgeon and is a Professor of Urology, Oncology, and Pathology at University of Rochester. At the University of Rochester School of Medicine and Dentistry(UR) in September 1995, Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney, testicle, penis and other genitourinary organs, carries on extensive research in the basic biology of bladder and prostate cancers, and has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of genitourinary cancers.

Dr. Messing has held numerous leadership positions in institutional, local , regional and national organizations including being a department chairman or over 22 years. interim director of the National Cancer Institute, URMC Cancer Center, being a board member, officer and president of both The Society of Urological Oncology and The North Western Section of the American Urological Association (NSAUA), co chairman of the Genitourinary Group (GU) of the Eastern Cooperative Oncology Group (ECOG) and co-leader of the Renal Cancer Subcommittee of the GU committee of SWOG. (The South West Oncology Group) In September, 2021 he will become the President-elect of the American Urological Association (AUA) to become President May, 2022.


Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.

His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of development and progression of cancers of the bladder, prostate and kidney, and bringing these studies to fruition for the detection, prevention and treatment of these diseases. He has also designed and conducted landmark phase III clinical trials for each of these cancers and has carried out the first screening trial for bladder cancer in a general population. Important work has included defining the roles of epidermal growth factor (EGF) and its cell surface receptor in urothelial carcinogenesis and progression, investigating polyamine synthesis inhibition as a means to prevent bladder and prostate cancers, in large phase III clinical trials studying DFMO's ability to prevent bladder cancer's recurrence, the timing of androgen deprivation therapy (ADT) in treating regionally advanced completely resected prostate cancer, the effectiveness of adjuvant alpha interferon for completely resected, locally extensive, renal cell carcinoma, and the role of a single intravesical instillation of gemcitabine in preventing recurrence of low grade non-muscle invading bladder cancer (NMIBC). He has also contributed importantly to trials testing various forms of intravesical therapy for high risk, NMIBC, and the value of radiation therapy after prostatectomy for stage pT3 prostate cancer. He has demonstrated the feasibility of screening for bladder cancer (using hematuria reagent strips) and has worked on the development and testing of several molecular markers for the detection of bladder cancer.

Furthermore, his clinical trial work continues as the study coordinator (PI) of a large phase III clinical trial of immediate post TURBT intravesical instillation therapy for prevention of recurrence of low risk bladder cancer.Much of the above mentioned work continues, but currently he is also investigating gender disparities in bladder cancer's incidence and outcome. These efforts have ranged from investigations using large, national data bases, to molecular studies in cells and transgenic animal models. Additionally, he along with his basic science collaborators are investigating the preventative and therapeutic roles of nuclear transcription factors, vitamins and related molecules in prevention and treatment of prostate and bladder cancer.



MD | New York University School of Medicine

Post-doctoral Training & Residency

09/01/1974 - 06/30/1978
Residency in Urology at Stanford University School of Medicine

09/01/1973 - 06/30/1974
Residency in Surgery (General Surgery) at Bellevue Hospital Center

09/01/1972 - 06/30/1973
Internship in Surgery (General Surgery) at Bellevue Hospital Center

VIEW ALL expand_more


SUO Distinguished Service Award
Sponsor: Society of Urological Oncology

Robert S. Davis Teaching Award
Sponsor: URMC, Department of Urology

Ramon Guiteras Award
Sponsor: American Urological Association

George E. Slotkin Lecturer
Sponsor: Northeast Section-AUA

SUO Medal Recipient
Sponsor: Society of Urologic Oncology

Presidential Citation Award
Sponsor: American Urological Association
Location: San Diego, California

2013 Best of Posters Award - AUA - 2013 Annual Meeting
Sponsor: American Urological Association
Location: San Diego, California

2012 Best of Posters Award – AUA – 2012 Annual Meeting
Sponsor: American Urological Association
Location: Atlanta, Georgia

2010 - Present
2010 Best of Posters Award - AUA - 2010 Annual Meeting
Sponsor: American Urological Association
Location: San Francisco, California

Davey Award
Sponsor: James P. Wilmot Cancer Center
Location: University of Rochester Medical Center

2007 - Present
American Association of Genitourinary Surgeons (AAGUS)

1999 - 1999
CaP Cure Award and Best Clincal Research Prostate Cancer
Sponsor: CaP Cure
Location: Best Clinical Research on Prostate Cancer

1986 - Present
Sponsor: American College of Surgeons
Location: American College of Surgeons

1985 - Present
Sigma Xi
Sponsor: The Scientific Research Society

1984 - 1986
Junior Faculty Clinical Fellow
Sponsor: American Cancer Society

1977 - 1977
First Prize for Clinical Research and the Bill Smart Award for Best Clinical Paper (Interstitial Cystitis)
Location: Northern California Urology Residents Seminar - Stanford, CA

1975 - 1975
Second Prize for Case Reports (Renal Arteriovenous Fistulas)
Location: Northern California Urology Residents Seminar - Davis, CA

1972 - Present
Alpha Omega Alpha
Location: New York University - School of Medicine

1972 - 1972
The Samuel Soifer Memorial Award for Outstanding Work in Urology - 1972
Location: New York University - School of Medicine

1968 - Present
Phil Beta Kappa
Location: University of Chicago

VIEW ALL expand_more


Patent Title: Pre- and Intra-Operative Imaging of Bladder Cancer
Patent #: 9,089,601
Issue Date: Jul 28, 2015
Country: United States
Invented By: Dragan J Golijanin, Aimee Johnson Henry, Edward M Messing, Jay Reeder, Ronald W Wood

Patent Title: Intraoperative Imaging of Renal Cortical Tumors and Cysts
Patent #: RE45,916
Issue Date: Mar 08, 2016
Country: United States
Invented By: Dragan J Golijanin, Edward M Messing, Ronald W Wood

Patent Title: Intraoperative Imaging of Renal Cortical Tumors and Cysts
Patent #: 8,725,225
Issue Date: May 13, 2014
Country: United States
Invented By: Dragan J Golijanin, Edward M Messing

VIEW ALL expand_more


Journal Articles

Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, Bylund K, Rosenzweig D, Hall W, De Ruyck K, Rosenstein BS, Stock RG, Gómez-Caamaño A, Vega A, Sosa-Fajardo P, Taboada-Valladares B, Aguado-Barrera ME, Parker C, Veldeman L, Fonteyne V, Bultijnck R, Talbot CJ, Paul Symonds R, Johnson K, Rattay T, Webb A, Lambrecht M, de Ruysscher D, Vanneste B, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Rancati T, Avuzzi B, Valdagni R, Azria D, Farcy Jacquet MP, Chang-Claude J, Seibold P, West C, Janelsins M, Chen Y, Messing E, Morrow G, . "Use of Angiotensin Converting Enzyme Inhibitors is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.. 2022 Jan 22; Epub 2022 Jan 22.

Zhang H, Yang H, Bandyopadhyay S, Milano MT, Fung C, Messing EM, Chen Y. "Increased risk of high-grade prostate cancer among testicular cancer survivors." PloS one.. 2022 17(2):e0263573. Epub 2022 Feb 14.

Ellis EE, Messing EM. "Active Surveillance of Small Renal Masses: A Systematic Review". Kidney Cancer. 2021; .

Books & Chapters

Chapter Title: HGT1 Bladder Cancer: Diagnosis and Treatment
Book Title: Bladder Cancer: Diagnosis and Clinical Management.
Author List: Gaya JM, Palou J, Messing EM
Edited By: Lerner S, Sternberg C, Schoenberg M
Published By: Wiley-Blackwell 2015

Chapter Title: Epidemiology and Natural History
Book Title: Bladder Cancer
Author List: Messing EM, Scosyrev E
Edited By: Konety B, Chang S
Published By: Springer 2014

Chapter Title: Bladder Cancer: Epidemiology, risk factors, screening and chemoprevention
Book Title: Essentials and Updates in Urologic Oncology, 1st Edition
Author List: Knopf J, Trivedi D, Messing EM
Published By: Nova Science Publishers, Inc. 2011




Edward M. Messing, M.D., UR Medicine Urology


At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.